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ABSTRACT 
 
The human p53 tumor suppressor, known as the “guardian of the genome”, is one of the most 
important molecules in human cancers. One mechanism for suppressing p53 uses its negative 
regulator, MDM2, which modulates p53 by binding directly to and decreasing p53 stability. 
In testing novel therapeutic approaches activating p53, we investigated the preclinical activity 
of the MDM2 antagonist, Nutlin-3a, in Philadelphia positive (Ph+) and negative (Ph-) 
leukemic cell line models, and primary B-Acute lymphoblastic leukemia (ALL) patient 
samples. In this study we demonstrated that treatment with Nutlin-3a induced grow arrest and 
apoptosis mediated by p53 pathway in ALL cells with wild-type p53, in time and dose-
dependent manner. Consequently, MDM2 inhibitor caused an increase of pro-apoptotic 
proteins and key regulators of cell cycle arrest. The dose-dependent reduction in cell viability 
was confirmed in primary blast cells from Ph+ ALL patients with the T315I Bcr-Abl kinase 
domain mutation. In order to better elucidate the implications of p53 activation and to identify 
biomarkers of clinical activity, gene expression profiling analysis in sensitive cell lines was 
performed. A total of 621 genes were differentially expressed (p < 0.05). We found a strong 
down-regulation of GAS41 (growth-arrest specific 1 gene) and BMI1 (a polycomb ring-finger 
oncogene) (fold-change -1.35 and -1.11, respectively; p-value 0.02 and 0.03, respectively) 
after in vitro treatment as compared to control cells. Both genes are repressors of INK4/ARF 
and p21. Given the importance of BMI in the control of apoptosis, we investigated its pattern 
in treated and untreated cells, confirming a marked decrease after exposure to MDM2 
inhibitor in ALL cells. Noteworthy, the BMI-1 levels remained constant in resistant cells. 
Therefore, BMI-1 may be used as a biomarker of response. Our findings provide a strong 
rational for further clinical investigation of Nutlin-3a in Ph+ and Ph-ALL. 
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1. INTRODUCTION 
 
1.1 Acute lymphoblastic leukemia 
Acute lymphoblastic leukemia (ALL) is a malignant disorder that originates from one single 
hematopoietic precursor committed to the B- or T-cell lineage1. ALL represents a biologically 
and clinically heterogeneous group of B/T-precursor-stage lymphoid cell malignancies arising 
from genetic insults that block lymphoid differentiation and drive aberrant cell proliferation 
and survival2.  
As a consequence there is accumulation of an immature B- or T cell clone in the bone marrow 
resulting in the suppression of normal hematopoiesis and in various extra-medullary sites. 80-
85% of ALL are B-cell lineage (B-cell precursor ALL), and 15-20% are T-cell lineage (T-
ALL). Normal lymphocyte ontogeny takes place in the central lymphoid organ: in the bone 
marrow for B-cells and in the thymus for T-cells. During the maturation process, specific cell 
surface receptors are triggered to initiate a program of a sequential gene expression that 
commits developing cells to a B- or T-cells fate, drives the proliferation of progenitors and 
initiates the rearrangement of antigen receptor genes. The acquisition and expression of a 
mature and unique antigen receptor is a central feature of both B- and T-cell maturation and 
very similar molecular and cellular events characterize the early development of B- and T-
cells1. 
Incidence and cure rates differ among children and adults. In children, ALL is the commonest 
malignancy accounting for approximately 25% of childhood cancer; in adults, this disease is 
less common and generally carries a worse prognosis. Although there is a remarkable 
progress made in the treatment of ALL in children and, with less efficacy in adults, several 
ALL subtypes continue to have a poor prognosis. 
Consequently there is the need to improve the molecular dissection of subtypes, identifying 
the genetic alterations that predict the risk of treatment failure, and developing novel and 
targeted therapies2. 
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1.2 Philadelphia chromosome 
In adult patients with B-ALL, the most frequent chromosomal translocation is the t(9;22). The 
Philadelphia chromosome (Ph+), arising from a reciprocal translocation between chromosome 
9 and 22 (Fig.1) was the first defined cytogenetic abnormality recognized as linked both 
chronic myeloid leukemia (CML) and Ph+ ALL. This translocation fuses the ABL1 oncogene 
on chromosome 9 to a breakpoint cluster region (BCR). It generates the constitutively 
activated BCR-ABL tyrosine kinase, which is responsible for both acute and chronic disease.  
In CML, a p210 Bcr-Abl isoform is initially expressed in hematopoietic stem cells capable of 
giving rise to both differentiated myeloid and lymphoid progeny; whereas, in de novo Ph+ 
ALL, the expression of p185 and p190 isoforms is restricted to the B-cell lineage.  
CML typically presents as an indolent myeloproliferative disease, CML chronic phase (CP), 
which, if untreated, invariably evolves to blast crisis (BC), in which poorly differentiated 
malignant myeloid or lymphoid blast cells become resistant to any therapeutic approach.  
Bcr-Abl expression increases during disease progression and promotes the acquisition of 
additional genetic changes, which are essential for the expansion of clones with greater 
malignant potential. From a clinical perspective, de novo Ph+ ALL resembles CML lymphoid 
BC, but without an initial CP. Treatment of CML and Ph+ ALL is represented by tyrosine 
kinase inhibitors (TKIs). CML-CP and Ph+ ALL differ in their aggressiveness and response to 
therapy; Ph+ ALL is associated with a rapid response to treatment but with frequent relapse 
and with poor outcome, whereas CML-CP is characterized by high and sustained rate of 
complete hematologic and cytogenetic responses3. 
 
Figure 1: The t(9;22) translocation and its products. The BCR-ABL oncogene on the Ph chromosome and the 
reciprocal ABL-BCR on the derivative 9q+ chromosome. 
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1.2.1 Structure and functions of the ABL and BCR proteins 
The ABL1 gene, spanning a 230 kb region at band 9q34, encodes a 145 kDa non-receptor 
tyrosine kinase. The ABL1 protein (Fig.2) has three SRC homology (SH) domains called 
SH1, SH2, and SH3; the SH1 domain has a tyrosine kinase function while the SH2 and SH3 
domains are involved in protein–protein interactions; they also regulate the tyrosine kinase 
activity and are necessary for signal transduction function. The ABL1 protein has also three 
nuclear localization signal (NLSs) domains and one nuclear export sequence (NES), three 
DNA-binding regions and an F-actin-binding domain4. 
The c-ABL has been implicated to function in a range of cellular processes. This protein can 
shuttle between the nuclear and the cytoplasmic compartment because of its NLSs and NES. 
Nuclear c-ABL plays a role in transcription regulation and can induce apoptosis in response to 
DNA damage. Cytoplasmic c-ABL is involved in actin dynamics and cell migration.  
c-ABL function is tightly controlled in order to prevent oncogenic activity; it’s regulated by 
intramolecular interactions that keep the kinase domain in a closed and inactive conformation. 
The c-ABL closed conformation involves the interaction between the SH3 domain and the 
proline-rich sequence present in SH2–kinase linker. In addition, c-ABL regulation implicates 
unique interactions that involve the SH2 domain, the myristoylation site and the first 80 N-
terminal amino acids of the protein, which has been named the “Cap”5. 
 
 
 
 
Figure 2: Schematic structure of the ABL protein. Type Ia isoform is slightly shorter than type Ib, which 
contains a myristoylation (myr) site for attachment to the plasma membrane. The SH domains are situated 
toward the NH2 terminus. Y393 is the major site of autophosphorylation within the kinase domain, and 
phenylalanine 401 (F401) is highly conserved in PTKs containing SH3 domains. The middle of protein is 
dominated by proline-rich regions (PxxP) capable of binding to SH3 domains, and it harbors 1 of 3 NLS. The C-
terminus contains DNA as well as G- and F-actin–binding domains. The arrowhead indicates the position of the 
breakpoint in the BCR-ABL fusion protein7. 
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Breakpoint cluster region (BCR) is a 160 kDa citoplasmatic protein. The BCR 
serine/threonine kinase contains multiple functional domains (Fig.3). Two domains in the C-
terminal half of the protein are homologous to regulators of small, Ras-related GTP-binding 
proteins: guanine nucleotide exchange factors and GTPase activating proteins for the p2l 
subfamily of GTPases6. The center of the molecule contains a region with dbl-like and 
pleckstrin-homology (PH) domains that stimulate the exchange of guanidine triphosphate 
(GTP) for guanidine diphosphate (GDP) on Rho guanidine exchange factors (Rho-GEF), 
which in turn may activate transcription factors. In addition, BCR can be phosphorylated on 
several tyrosine residues, especially tyrosine 177 which binds Grb-2, an important adapter 
molecule involved in the activation of the Ras pathway7. 
 
 
 
 
Figure 3: Structure of the BCR protein. The dimerization domain (DD) and the 2 cyclic adenosine 
monophosphate (cAMP) kinase homologous domains are situated in the N-terminus. Y177 is the 
autophosphorylation site crucial for binding to Grb-2. The center of the molecule contains a region homologous 
to Rho-GEF as well as dbl-like and PH domains. Toward the C-terminus a putative site for calcium-dependent 
lipid binding (CaLB) and a domain with activating function for Rac-GTPase (Rac-GAP) are found. Arrowheads 
indicate the position of the breakpoints in the BCR-ABL fusion proteins7. 
 
 
1.2.2 BCR-ABL fusion gene 
Depending on the precise breakpoints in the translocation and RNA splicing, different forms 
of BCR–ABL protein with different molecular weights (p185 BCR-ABL, p210 BCR–ABL 
and p230 BCR–ABL) can be generated in patients8 (Fig.4).  
The breakpoints within the ABL gene at 9q34 can occur anywhere over a large (greater than 
300 kb) area at its 5’ end, either upstream of the first alternative exon Ib, downstream of the 
second alternative exon Ia, or, more frequently, between the two9. 
In most patients with CML, the break in BCR gene occurs within a 5.8-kb area spanning BCR 
exons 12-16 (originally referred to as exons b1-b5), defined as the major breakpoint cluster 
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region (M-bcr). Because of alternative splicing, fusion transcripts with either b2a2 or b3a2 
junctions can be formed. A 210-kDa chimeric protein (P210BCR-ABL) is derived from this 
mRNA. In patients with ALL and rarely in patients with CML, the breakpoints are further 
upstream in the 54.4-kb region between the alternative BCR exons e2’ and e2, termed the 
minor breakpoint cluster region (m-bcr). The resultant e1a2 mRNA is translated into a 190-
kDa protein (P190BCR-ABL). A third breakpoint cluster region (μ-bcr) was identified 
downstream of exon 19, giving rise to a 230-kDa fusion protein (P230BCR-ABL) associated with 
the rare Ph+ chronic neutrophilic leukemia10. 
 
 
 
 
 
Figure 4: Locations of the breakpoints in the ABL and BCR genes and structure of the chimeric BCR/ABL 
mRNA transcripts derived from the various breaks. 
 
 
1.2.3 Roles of BCR-ABL in leukemogenesis 
In contrast to ABL, BCR-ABL exhibits deregulated, constitutively active tyrosine kinase 
activity and is found exclusively in the cytoplasm of the cell, complexed with a number of 
cytoskeletal proteins7. 
BCR-ABL expression regulates a variety of signaling molecules ranging from mitogens, 
antiapoptotic proteins, hematopoietic factors, and cytoskeletal components, to negative 
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regulators such as phosphatases (Fig.5). The key pathways implicated so far are those 
involving RAS, mitogen-activated protein (MAP) kinases, signal transducers and activators of 
transcription (STAT), phosphatidylinositol 3-kinase (PI3K), and MYC11. 
BCR-ABL interacts with the cytoplasmic protein GRB2 and the BCR-ABL/GRB2 complex 
recruits Son of Sevenless (SOS), which is constitutively associated with the GRB2 SH3 
domain. In turn, the BCR-ABL/GRB2/SOS complex stimulates conversion of the inactive 
GDP-bound form of Ras to its active GTP-bound state and the activation of the scaffold 
adapter GRB2-associated binding protein 2 (GAB2). As a consequence, the 
GRB2/GAB2/SOS complex causes constitutive activation of the RAS downstream pathway, 
thereby activating MAP extracellular signal-regulated kinase (ERK)1/2 (MEK) and MAP 
kinase proteins and resulting in abnormal cell proliferation8. 
In addition, this complex activates the PI3K/AKT pathway, which promotes survival by 
suppressing the activity of the forkhead O (FOXO) transcription factor, and enhances cell 
proliferation by inducing p27 proteosomal degradation and by mTOR activation. BCR-ABL 
may activate PI3K by more than one pathway. Once activated, PI3K activates AKT kinase, 
which serves as a key downstream effector by exerting many cellular effects through the 
phosphorylation of downstream substrates that regulate the apoptotic machinery, resulting in 
prolonged survival and expansion of the abnormal clone12. 
Among the key transcription factors involved in BCR-ABL signaling, STAT1 and STAT5 are 
constantly active in Ph+ CML patients. In normal cells, nuclear translocation of STATs occurs 
exclusively after cytokine binding to receptors and is mediated by activation of the receptor-
associated JAK kinases13. By contrast, in CML, STATs seem to be activated in a JAK-
independent manner through a direct association of STAT SH2 domains with phosphorylated 
tyrosines on BCR-ABL. Activation of STAT5 is at least partially responsible for protection 
from programmed cell death through the upregulation of the antiapoptotic molecule BCL-xL 
together with the inactivation of the proapoptotic molecule BAD by AKT14.  
Another target of the transforming activity of the BCR-ABL protein is the proto-oncogene 
MYC, transcription factor that regulates apoptosis and cell cycle, which is expressed at a high 
level in CML cells. MYC activation seems to be independent of the RAS pathway but directly 
upregulated by the ABL SH2 region15. 
BCR-ABL is involved in the inhibition of apoptosis because it may block the release of 
cytochrome C from the mitochondria and thus the activation of caspases. This effect upstream 
of caspase activation might be mediated by the Bcl-2 family of proteins. BCR-ABL has been 
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shown to up-regulate Bcl-2 in a Ras- or a PI3 kinase-dependent manner. Moreover, BclxL is 
transcriptionally activated by STAT5 in BCR-ABL–positive cells. The survival signal 
provided by BCR-ABL is at least partially mediated by Bad and requires targeting of to the 
mitochondria, where Raf-1 phosphorylates Bad on serine residues. BCR-ABL, also, inhibits 
apoptosis by down-regulating interferon consensus sequence binding protein (ICSBP)7. 
 
 
Figure 5: Signal-transduction pathways affected by BCR-ABL. The cellular effects of BCR-ABL are exerted 
through interactions with various proteins that transduce the oncogenic signals responsible for the activation or 
repression of gene transcription, of mitochondrial processing of apoptotic responses, of cytoskeletal 
organization, and of the degradation of inhibitory proteins11. 
 
1.3 Treatment of Ph+ ALL 
Ph+ ALL is associated with poor prognosis. The outcome of ALL patients with the standard 
chemotherapy was improved with the incorporation of the TKI Imatinib Mesylate into 
frontline therapy. Unfortunately, in most cases these responses are rapidly lost despite 
persistent treatment3. Several highly potent second-generation BCR-ABL inhibitors have been 
developed to overcome Imatinib resistance and improve the prognosis of patients with CML 
and ALL. These include novel and more potent multi-TKIs such as Dasatinib, and potent 
selective BCR-ABL inhibitors such as Nilotinib13, that typically induces a high rate of 
hematological and cytogenetic responses3. However, resistance or intolerance to these TKIs 
still leaves some patients without many treatment options. One point mutation in particular, 
the T315I mutation, has been shown to be resistant to first and second generation TKIs.  
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The third generation TKI, Ponatinib, may provide an option for these patients16. 
Most BCR-ABL inhibitors can be classified as either a type 1 or type 2 inhibitor compound, 
depending on their binding interactions with BCR-ABL. Type 1 inhibitors target the ATP-
binding site of the enzyme in the active form, which is characterized by an open conformation 
of the activation loop, referred to as DFG “in” based on the position of the conserved triad 
aspartate-phenylalanine-glycine (DFG) at the beginning of the activation loop.  
The common feature of the type I compounds is their ability to bind to the ATP site 
mimicking the adenine ring in its interactions with the “hinge” residues of the protein.  
In contrast, type 2 inhibitors, or DFG-out compounds, are the inactive forms subsequently 
developed to bind to an additional hydrophobic site in addition to the same area as type 1 
compounds. The ability to bind to an additional hydrophobic site provides type 2 inhibitors 
with the ability to be more selective and more potent than type 1 inhibitors. Examples of 
DFG-in inhibitors include Dasatinib, while DFG-out inhibitors include Imatinib, Nilotinib, 
and Ponatinib17. 
 
1.3.1 Tyrosine Kinase Inhibitors: 
- Imatinib. Imatinib, a small-molecule TKI, was the first drug to be developed that was 
able to directly target BCR-ABL tyrosine kinase activity and to be tested in CML13. Imatinib 
mesylate (Glivec, previously known as STI571), a potent inhibitor of the tyrosine kinases 
ABL, ARG, platelet-derived growth factor receptor (PDGFR) and KIT, has been shown to 
selectively induce apoptosis of BCR-ABL cells and is remarkably successful in treating 
patients with CML and ALL Ph+8. Imatinib resistance has been attributed to BCR-ABL 
dependent and independent mechanisms. BCR-ABL dependent mechanisms include 
amplification of the BCR-ABL gene and mutations within ABL that reactivate BCR-ABL and 
disrupt binding to the drug target. BCR-ABL point mutations are most common in the ATP-
binding pocket (P-loop), the contact site (T315 and F317), the SH2 binding site (M351), and 
the A-loop. A common mutation that occurs frequently after Imatinib therapy in Ph+ ALL 
patients is the glutamic acid to lysine mutation at codon 255 (E255K). 
Gatekeeper mutations (T315I and F317L) impede contact between Imatinib and BCR-ABL 
and, thus, contribute to Imatinib resistance and resistance to other second-generation TKIs. 
BCR-ABL-independent mechanisms include chromosomal abnormalities in addition to the Ph 
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chromosome abnormality, such as disruptions in drug uptake and efflux, and activation of 
alternative signaling pathways that cause proliferation or promote cell survival18. 
 
- Dasatinib. Dasatinib blocks BCR-ABL at low concentrations but is less selective than 
Imatinib. Similarly to Imatinib, it inhibits BCR-ABL, Kit, and PDGFR, but in contrast, it also 
blocks Src, Tec and Ephrin (Eph) kinases, as well as many other kinases13. 
 
- Nilotinib. Nilotinib inhibits kinase targets including BCR-ABL, PDGFR, and c-Kit, but 
not the Src family kinases16. Nilotinib blocks BCR-ABL at lower concentrations than does 
Imatinib, but, like Imatinib, it appears to be more selective than Dasatinib in targeting 
tyrosine kinases13. This highly specific BCR-ABL inhibitor is approximately 30-fold more 
potent than Imatinib and is active in vitro against 32 of 33 BCR-ABL mutations. BCR-ABL 
P-loop mutations (Y253F/H or E255K/V) are resistant to Nilotinib18. 
 
- Bosutinib. Bosutinib (SKI-606) is a small molecule, dual Src/ABL TKI, with potent 
preclinical BCR-ABL inhibitory activity in Imatinib-resistant CML cell lines. Unlike other 
second-generation TKIs, Bosutinib exhibits minimal inhibitory activity against c-KIT or 
PDGRF19. Bosutinib demonstrated preclinical activity against most Imatinib-resistant mutants 
of BCR-ABL, including Y253F, E255K and D276G, with the exception of T315I and V299L. 
It is able to bind to both inactive and intermediate conformations of BCR-ABL3. 
 
- Ponatinib. Ponatinib is a synthetic, multi-targeting TKI structurally designed as a pan-
BCR-ABL inhibitor. This is reflected by the inhibition of in vitro tyrosine kinase activity of 
ABL and T315I mutant ABL with a half maximal inhibitory concentration (IC50) of 0.4 nM 
and 2.0 nM, respectively. Ponatinib also inhibits the in vitro activity of additional oncogenic 
kinases, including members of the vascular endothelial growth factor receptor (VEGFR), 
PDGFR, fibroblast growth factor receptor (FGFR), Eph receptor, Src family kinases, c-Kit, 
RET, TIE2, and FLT3. The Ponatinib molecule is designed to interact with T315I in a 
different manner than the existing kinase inhibitors. Ponatinib was designed to avoid binding 
with the side chain of T315I in native BCR-ABL, and instead forms beneficial van der Waals 
interactions with the isoleucine side chain of the T315I mutant. This, coupled with its ability 
to accommodate the steric hindrance from mutations in the isoleucine variant, allows it to 
bind to and inhibit the ABL kinase activity of T315I point mutations16. 
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1.4 Novel alterations in ALL 
The ALL cells carry numerous genetic alterations. Translocation resulting in the creation of 
fusion genes are frequently found, like t(12;21) encoding the ETV6-RUNX1 or fusions of 
MLL with various partner genes in childhood B-ALL; genomic deletions classically lead to 
the loss of tumor-suppressor gene like cyclin-dependent kinase inhibitor 2A gene, CDKN2A, 
encoding a cell cycle regulator. In B-cell precursor ALL, genome wide analyses have 
identified deletions and/or inactivating mutations of genes encoding regulators of B-cell 
development like PAX5, EBF1 and IKZF11.  
 
1.4.1 Ikaros  
The Ikaros (IKZF1) gene encodes a family of zinc finger transcription factors that are 
important regulators of hematopoietic lymphoid development and differentiation (Fig.6). 
Ikaros is transcribed as a number of isoforms due to alternative splicing that essentially alter 
the expression of exons 3–5 coding for the N-terminal DNA binding domain. Long isoforms 
(Ik1 to Ik3) with at least three zinc fingers can bind efficiently to DNA, while shorter versions 
(Ik4 to Ik8) behave as dominant negative isoforms upon heterodimerization. These short 
isoforms are normally expressed at low levels compatible with their potential regulatory role 
on the activity of the predominant Ik1 and Ik2 isoforms. Due to the important consequences 
stemming from a diminution of Ikaros activity, it is conceivable that abnormalities in the 
splicing regulation of Ikaros transcripts could lead to significant pathological manifestations.  
The role of Ikaros in lymphoid development is illustrated by the complete lack of lymphoid 
cells following gene inactivation by targeted deletion of exons 3–5, which generates a 
dominant negative Ikaros isoform. 
While Ikaros is expressed throughout the ontogeny of lymphoid cells, a diminution of Ikaros 
activity in T lymphocytes, by means of over-expression of a dominant-negative isoform, 
causes hyperproliferation, loss of heterozygosity and malignant T cell development20. 
Genetic alteration of IKZF1 is associated with a very poor outcome in B-cell–progenitor ALL. 
Deletions or mutations of IKZF1 were identified as predictors of poor outcome which are 
associated with a high risk of relapse in ALL21. IKZF1 deletion is the most frequent somatic 
copy number alteration in Ph+ ALL. It is likely that Ikaros loss combines with BCR-ABL1 to 
induce lymphoblastic leukemia, arresting B-lymphoid maturation22. 
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Figure 6: Schematic structure of Ikaros functional domains. The N-terminal zinc fingers are responsible for 
DNA binding. The C-terminal zinc fingers are essential for homo- and hetero-dimerization. 
 
1.4.2 Pax5 
PAX5 (paired-box domain 5) is the guardian of the B-cell identity. This transcription factor 
belongs to the family of paired-box domain transcription factors (Fig.7). 
Its expression is initiated during early stages of B-cell differentiation beginning at the pro-B 
stage, and is turned off to allow terminal B-cell differentiation. PAX5 is thus involved both in 
the maintenance of B-cell identity and in the control of terminal B-cell differentiation23. 
 
 
Figure 7: Schematic structure of PAX5 functional domains. The PAX5 structure consists of a DNA binding 
paired domain (PD), conserved octapeptide (OP), partial homeodomain (HD), transactivation domain (TA) and 
inhibitory domain (ID). 
 
PAX5 is frequently mutated in adult B-cell progenitor ALL24. PAX5 genomic deletions, 
ranging from a complete loss of chromosome 9 to the loss of a subset of exons, were 
identified in BCR-ABL1 ALL patients25. B-ALL is also characterized by the participation of 
PAX5 in specific chromosomal translocations that generate novel transcription factors by 
fusing the N-terminal DNA-binding domain of PAX5 with C-terminal regulatory sequences 
of a second transcription factor. Surprisingly, these PAX5 translocations involving several 
different partner genes, as PAX5-ETV6, PAX5-FOXP1, PAX5-EVI3 and PAX5-ELN, have so 
far been identified in B-ALL26. 
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1.4.3 9p21 Locus 
The chromosomal region of 9p is a frequent site of loss or deletion in several human cancers, 
such as glioma (60%), head and neck cancers (50%) and bladder cancers (45%)27. 
High frequencies of 9p21.3 deletions, ranging from 18% to 45%, have been documented also 
in ALL 28,29. 
 
1.5 CDKN2A and CDKN2B genes 
Two important tumor suppressor genes, CDKN2A and CDKN2B situated on 9p21 locus, 
encode three critical factors, p14ARF, p16INK4a and p15INK4b (Fig.8), involved in cell cycle 
regulation and apoptosis30. The INK4a/ARF locus span approximately 30 kb of genomic DNA 
and comprise four exons. The Alternative Reading Frame, also called p14ARF, is derived 
from a distinct first exon (exon 1β), originating approximately 19 kb centromeric to the first 
exon of p16INK4a (exon 1α) and 23 kb centromeric to exon 2. Exon 1β, under the control of its 
own promoter, is spliced to the second and third exons that are separated by 3 kb of intronic 
sequence and are shared with p16INK4a. The open reading frame of the 1.1 kb p14ARF 
transcript is terminated within exon 2, with exon 3 comprising an untranslated 3’ exon31. 
CDKN2b has its own open reading frame and it encodes p15INK4b. 
 
 
Figure 8: p16 and p14 proteins are encoded in alternative reading frames, are not isoforms and have no amino 
acid homology. Instead p16 and p15 are homologous inhibitors of the cyclin-dependent kinases, and are 85% 
similar at the amino acid level32.  
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1.5.1 p15INK4a and p16INK4b proteins 
The INK4 cell-cycle inhibitors, p15INK4a, p16INK4b, p18INK4c and p19INK4d are homologous 
inhibitors of the cyclin-dependent kinases, CDK4 and CDK6, which promote proliferation33. 
The INK4 proteins bind to CDK4 and CDK6 and inhibit their kinase activity for 
Retinoblastoma (Rb) protein family, and perhaps other CDK targets (Fig.9).  
As opposed to the CIP/KIP inhibitors of cyclin dependent kinases, INK4 binding induces an 
allosteric change that abrogates the binding of the cyclin dependent kinases with the D-type 
cyclins, which are required for catalytic activity, inhibiting CDK4/6-mediated 
phosphorylation of Rb family members. The expression of p16INK4a or other INK4 members, 
therefore, produces decreased CDK4/6 kinase activity and Rb hypophosphorylation, which in 
turn leads to E2F repression and growth arrest32.  
The Rb protein is one of the key regulators of various stages of cell development. It regulates 
transmission from extracellular signals and controls the response of a cell to these signals. In 
cycling cells, Rb regulates progression through and exit from the cell cycle, and also regulates 
permanent withdrawal from the cell cycle preceding differentiation34. 
Thus, expression of p15INK4b or p16INK4a maintains Rb-family proteins in a 
hypophosphorylated state, which promotes binding E2F to effect a G1 cell-cycle arrest.  
The transition from the G1 to the S phases of the cell cycle marks an irreversible commitment 
to DNA synthesis and proliferation and is strictly regulated by positive and negative growth-
regulatory signals. The G1-S transition is controlled by the Rb-E2F pathway, which links 
growth-regulatory pathways to a transcription program required for DNA synthesis, cell cycle 
progression, and cell division. This transcription program is activated by the E2F transcription 
factors and repressed by E2F-Rb complexes. In quiescent cells or cells in early G1, the Rb 
protein binds to the E2F transcription factors and blocks their transactivation domain. 
Mitogenic growth factors lead to the sequential activation of the CDK-Cyclin CDK4/6-
CyclinD and CDK2-CyclinE, which hyperphosphorylate Rb and thereby cause the release of 
active E2F. The Rb pathway thus ensures that S phase entry strictly depends on growth-factor 
signals. The importance of Rb in the control of cell proliferation is underscored by the 
deregulation of this pathway in a majority of cancer cases, which occurs either by mutation or 
deletion of Rb, or by alterations in the upstream CDK, Cyclin, and CDK-inhibitory proteins35. 
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1.5.2 ARF protein  
ARF protein comprises 132 amino acids with a molecular weight of 13,902 Da31.  
It suppresses aberrant cell growth in response to oncogene activation by inducing the p53-
pathway (Fig.9). ARF induction of p53 is mediated through two ubiquitin ligases, murine 
double minute 2 (MDM2), a RING finger oncoprotein, and ARF-binding protein 1/Mcl-1 
ubiquitin ligase E3 (ARF-BP1/Mule), a HECT (homology to E6-AP C-terminus) containing 
protein. Both MDM2 and ARF-BP1 act as specific E3 ubiquitin ligases for p53, are highly 
expressed in various types of tumors, and have the potential to abrogate the tumor-suppressor 
functions of p53. ARF associates with MDM2 to inhibit the ubiquitination, nuclear export and 
subsequent degradation of p53. ARF physically sequesters MDM2 in nucleoli, thus relieving 
nucleoplasmic p53 from MDM2-mediated degradation32.  
Nucleolar relocalization of MDM2 is not required for p53 activation and that the 
redistribution of ARF into the nucleoplasm enhances its interaction with MDM2 and its p53-
dependent growth suppressive activity31. 
In addition to MDM2, ARF-BP1 is a key regulator of the p53 cell cycle regulatory pathway; 
ARF-BP1 directly binds and ubiquitinates p53 in an MDM2-independent manner. 
Unexpectedly, ARF-BP1 also ubiquitinates and promotes the degradation of the anti-
apoptotic bcl-2 family member, Mcl-1, and down-regulation of ARF-BP1 expression can also 
render cells more resistant to killing by genotoxic agents. Thus, ARF-BP1 has been assigned 
both anti-apoptotic (via p53 degradation) and pro-apoptotic (via Mcl-1 degradation) 
functions. Following aberrant oncogene activation, ARF expression is induced and inhibits 
ARF-BP1 activity toward p53 in the nucleus, thereby leading to p53-dependent cell cycle 
arrest or apoptosis. In the cytoplasm, where ARF is not abundant, oncogene activation may 
lead to ARF-BP1 mediated Mcl-1 degradation further promoting apoptosis36.  
ARF also enhances p53 function by promoting the phosphorylation and inhibiting the 
transcriptional activity of the RelA NF-kB subunit. The NF-kB family of transcription factors 
display anti-apoptotic activity and antagonize the p53 pathway through induction of MDM2 
and repression of p53. Thus, by counteracting the functions of Rel A, ARF increases the 
effectiveness of the p53 pathway37.  
Several p53-independent functions of ARF have also been reported. ARF has been reported to 
interact with multiple proteins other than MDM2, including E2F-1, MDMX, HIF-1α, 
topoisomerase I, MYC, and nucleophosmin (NPM).  
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The best characterized interaction is that between ARF and NPM. NPM, also known as B23, 
is a protein that shuttles between the nucleolus and cytoplasm and is involved in several 
cellular processes including ribosome processing and centrosome duplication. The interaction 
of ARF with B23 is important to regulate ribosome biogenesis by retarding the processing of 
early 47S/45S and 32S rRNA precursors32.  
The ARF-NPM interaction modulates ARF protein stability. Additionally, it appears that this 
interaction sequesters ARF in the nucleolus thus preventing it from binding MDM2. Specific 
point mutations of the C-terminus of NPM are noted in 30% of cases of primary adult acute 
myelogenous leukemia (AML)38.  
These mutant forms of NPM appear constitutively localized to the cytoplasm but retain the 
ability to bind ARF. Therefore, these mutations are believed to compromise the ARF-p53 
pathway both by decreasing ARF’s protein stability and by mislocalizing ARF to the 
cytoplasm where it is unable to inactivate MDM239,33.  
ARF can promote the conjugation of the small ubiquitin-like protein SUMO-1 to its binding 
partners, including MDM2 and B2332. 
 
 
 
 
Figure 9: p15 INK4b and p16INK4a inhibit CDK4/6 activity producing RB phosphorylation, which induces cell 
cycle arrest. p14ARF inhibits MDM2-mediated degradation of p53. 
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1.5.3 CDKN2A and CDKN2B alteration in ALL 
Inactivation of the tumor suppressor genes, CDKN2A and CDKN2B, can occur by deletion, 
methylation or mutation28. In the hematopoietic system, the INK4-ARF locus functions as a 
master regulator of Rb and p53 function to prevent inappropriate progenitor cell self-renewal 
and to eliminate incipient cancer cells driven by sustained oncogenic signaling40.  
Williams et al. induced BCR-ABL ALL in mouse models in which they demonstrated that 
ARF gene loss enhances oncogenicity, high aggressive lympholeukemia and limits imatinib 
response. In mouse bone marrow cells, transduced with retroviral vectors encoding p210 
BCR-ABL and p185 BCR-ABL isoforms, occurred B cell lympholeukemias when 
transplanted into lethally irradiated mice. If the activity of the ARF tumor suppressor is 
compromised, these donor cells initiate a much more highly aggressive and rapidly fatal 
disease. When mouse bone marrow cells expressing BCR-ABL are placed in short-term 
cultures selectively designed to support the outgrowth of pre-B cells, only those lacking one 
or two ARF alleles can initiate lympholeukemias when inoculated into immunocompetent, 
syngeneic recipient mice. Although the ABL kinase inhibitor Imatinib mesylate provides 
highly effective treatment for BCR-ABL-positive CML, it has proven far less efficacious in 
the treatment of BCR-ABL-positive ALLs, many of which sustain deletions of the INK4A-
ARF, CDKN2A, tumor suppressor locus. Mice receiving ARF-/- or ARF+/- p210 BCR-ABL-
positive pre-B cells do not achieve remission when maintained on high doses of oral imatinib 
therapy and rapidly succumb to lympholeukemia41.  
In mice, the combination of BCR-ABL expression and ARF loss are sufficient to induce 
aggressive B-cell ALL. Constitutive BCR-ABL kinase activity triggers ARF expression and 
induces p53-dependent apoptosis, thereby countering BCR-ABL’s proliferative effects. 
However, ARF inactivation cancels BCR-ABL-induced apoptosis and endows the cells with 
increased self-renewal capacity. Hence, ARF inactivation enables the BCR-ABL kinase to 
enforce unfettered B-cell proliferation, differentiation to the pre-B-cell stage, and guarantees 
acquisition of full leukemic potential42.  
Genomic deletion of CDKN2A is more prevalent alteration in childhood ALL than either 
hypermetilation or mutation43. 
The CDKN2A locus was deleted in ALL patient set of adolescents and young adults; in 
particular, homozygous deletions were found in 76% of the analyzed cases29. 
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It’s been reported that CDKN2A/ARF loss was detected in 29% of BCR-ABL1-positive ALL 
patients at diagnosis while CDKN2B loss was detected in 25% of cases; genomic deletions on 
9p21 locus were predominantly monoallelic and in 57% of leukemia cases the minimal 
overlapping region of the lost area was considerably large, eliminating a large number of 
genes. At relapse, a strong trend in the detection rate of CDKN2A/ARF loss (47%) compared 
with diagnosis was found, suggesting that loss of this genomic region may be involved in 
disease progression. In this study, CDKN2A, CDKN2B and ARF mutations were found at very 
low levels. Moreover, frequent nucleotide variations, were identified in exon 2 and 3 of 
CDKN2A: rs3731249 G/A, rs11515 C/G and rs3088440 C/T. These SNPs have been 
phenotypically associated with other tumors. Deletions of CDKN2A/B were significantly 
associated by univariate analysis with higher white blood cell (P=0.0291) and with poor 
outcome in terms of overall survival (P=0.0206), disease free survival (DFS) (P=0.0010), and 
cumulative incidence of relapse (P=0.0014). The negative prognostic impact of CDKN2A/B 
deletion on DFS was thereafter also confirmed by a multivariate analysis (P=0.0051)28. 
Because the loss of CDKN2A/B eliminates the critical tumor surveillance mechanism and 
allows proliferation, cell growth and tumor formation by the action of MDM2 and CDK4/6, 
attractive drugs could be represented by the inhibitors of MDM2 and CDK4/CDK6. 
 
1.6 Tp53 gene 
The Tp53 gene encompasses 16-20 kb of DNA on the short arm of human chromosome 17. 
This gene is composed of eleven exons, the first of which is noncoding and localized 8-10 kb 
away from the exons 2-11. The Tp53 gene has been conserved during evolution. In cross-
species comparison, the p53 proteins show five highly (>90%) conserved regions among the 
amino acid residues 13-19, 117-142, 171-181, 234-258, and 270-28644.  
Mammalian genomes contain three members of the p53 family, p53, p63, and p73 genes 
located on chromosomes 17p13.1, 3q27-29, and 1p36.2-3, respectively (Fig.10). These genes 
encode proteins with similar domain structures and significant amino acid sequence 
homology in the transactivation, DNA-binding and oligomerization domains. However, only 
one member has been identified in invertebrates, suggesting that the mammalian Tp53 gene 
family is derived from the triplication of one ancestral gene45.  
The human Tp53 gene contains an internal promoter in intron-4, confirming that the Tp53 
gene has a dual gene structure like its homologous genes Tp63 and Tp73. Moreover, intron-9 
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of the Tp53 mRNA can be spliced in three different ways, leading to the expression of p53 
proteins with different C-terminal domains. The intron-2 of human Tp53 mRNA can also be 
alternatively spliced, leading to the expression of p53 proteins deleted of the first 40 amino 
acids. Altogether, the human Tp53 gene can express nine different forms of the p53 protein 
containing different domains of the protein because of alternative splicing, alternative 
promoter usage, and alternative initiation of translation46. 
 
 
 
Figure 10: Schema of the Tp53, Tp63 and Tp73 genes of Homo sapiens. TP53, TP63, and TP73 genes have two 
promoters (P1 and P2). The P1 promoters produce transactivation-competent full-length proteins (TA) while the 
P2 promoters produce TAD-deficient proteins (ΔN) with dominant-negative functions. p53 gene transcription is 
initiated from two distinct sites (P1 and P1’). 
 
1.6.1 p53 protein structure  
The product of Tp53 gene is a 393-amino acid nuclear phosphoprotein (about 53 kDa in 
molecular weight). p53 was first described in 1979 as a protein that binds to the simian virus 
(SV40) large T antigen44,47. The p53 protein is divided into regions highly conserved during 
evolution. The protein is composed of: an N-terminal transactivation domain (amino acid 1-
42), a region rich in proline residues (amino acid 63-97) involved in the induction of 
apoptosis, a core sequence-specific DNA-binding domain (amino acid 102-292), containing 
most of the inactivating mutations found in different types of human cancers46,48, a 
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tetramerization domain (amino acid 323-356), and a C-terminal region (amino acid 363-393) 
(Fig.11). This C-terminal region of p53 binds to the N-terminal domain of MDM2. In 
addition, there are also NES for exporting to the cytoplasm at the N- and C-terminal ends, as 
well as NLS at the C-terminal end, enabling the regulation of subcellular localization of 
p5348,49. 
 
 
Figure 11: The p53 domain structure. The N-terminal region contains the transactivation domain (1–62) and a 
proline-rich region (63–97). The core domain (102–292) contains specific DNA binding sites. The C-terminal 
region includes the tetramerization domain (325–360) and a negative autoregulatory domain. NES signals exist 
on both N- and C-terminal, whereas NLS signals are located on C-terminal region. 
 
1.6.2 p53 expression  
The p53 protein was found in very low quantities in normal cells, due to its short half-life. In 
contrast, larger quantities of p53 (5-100-fold) could be detected in transformed cells in culture 
and in human tumors, due to increased half-life and an altered p53 conformational structure50. 
 
1.6.3 p53 protein regulation 
p53 activity is controlled by two broad mechanisms. First, is a complex array of post-
translational modifications, such as phosphorylation, sumoylation, or acetylation, which affect 
its ability to engage with relevant co-activators or negative regulators. This in turn determines 
p53 stability and abundance, and its ability to productively engage chromatin to regulate 
downstream target genes and micro-RNAs. Second, are mechanisms that control the stability 
and/or activity of its negative regulators, most significant of which are the related RING 
domain proteins, MDM2 and MDMX (also known as MDM4). The protein p53 can be also 
regulated by cytoplasmic or nuclear localization51. 
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1.6.4 p53 function 
p53 is a transcription factor that binds directly and specifically as a tetramer to target 
sequences of DNA through p53-responsive elements (p53REs) to transactivate several genes 
involved in p53 tumor suppressor activities such as p21 (cell-cycle arrest), Puma and Scotin 
(apoptosis)44.  
In response to a myriad of stress signals, the p53 protein is activated and thereafter depending 
on the tissue type and the extent of the cellular damage, triggers adequate cellular response 
including cell-cycle arrest, in G1 phase, and programmed cell death thus preventing the 
multiplication of damaged cells that could lead to cancer formation. Hence, p53 has been 
dubbed “the guardian of the genome”52,53.  
Multiple stimuli such as ionizing radiations, DNA damage, nitric oxide, hypoxia, 
chemotherapeutic agents, or oncogenic stimuli can activate p53. In response to various 
stimuli, p53 undergoes different changes and this activation could induce different effects. 
p53 is a transcription factor involved in the control of G1/S and G2/M phase transition, in 
DNA repair, and in induction of senescence, apoptosis, survival, autophagy, mitotic 
catastrophe54 (Fig.12): 
 
Cell Cycle Regulation. p53 regulates the control of the G1 checkpoint and can induce an 
arrest of the cell cycle, repair or apoptosis if DNA lesions are extensive55. Wild-type p53 
protein can transcriptionally transactivate p21Cip1, a potent inhibitor of most cyclin-
dependent kinases, involved in the cell cycle arrest56.  
p53 also stimulates the expression of the 14-3-3σ protein that sequesters the cyclin B1/CDK1 
complex to block the transition G2/M. But p53 also induces the expression of many others 
genes such as GADD45, which interacts with PCNA to inhibit the passage to S phase, or 
Reprimo to block the cell cycle in G2 phase54. 
 
Cell Senescence. The p53 tumor suppressor seems to play a critical role in the induction and 
maintenance of cellular senescence. p53 activation is an essential step in the induction of 
senescence following DNA damage or other forms of stress. In the context of senescence, p53 
is controlled by ATM/ATR and Chk1/Chk2 proteins which cause the posttranslational 
stabilization of p53 through its phosphorylation54. 
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Apoptosis. p53 can transactivate the cell death receptors CD95 or TNF which induce the 
formation of the DISC complex and finally activate caspase 8. p53 also activates proapoptotic 
members of the Bcl2 family: Bax, Noxa, and Puma-involved in the permeabilization of the 
outer mitochondrial membrane. Moreover, p53 has a direct role in cell death initiation by 
localizing to mitochondria and regulating mitochondrial outer membrane permeabilisation 
directly. Thus, p53 protein can directly induce permeabilisation of the outer mitochondrial 
membrane by forming complexes with the protective BclXL and Bcl2 proteins, resulting in 
cytochrome C release57. 
 
Autophagy. p53 can activate but also inhibit autophagy. Under stress, p53 can activate its 
target gene in the nucleus, such as AMP-activated protein kinase (AMPK) β1 and β2, 
deathassociated protein kinase1 (DAPK-1), and damage-regulated autophagy modulator 
(DRAM) favoring lysosomal degradation of intracellular components and adaptation to stress 
and cell survival. Cytoplasmic, but not nuclear, p53 is able to repress autophagy58. 
 
Mitotic Catastrophe. In response to DNA damage, checkpoints are activated to delay cell 
cycle progression and to coordinate repair. The absence of p53 might increase mitotic 
catastrophe58. p53-deficient cells in an unchecked tetraploid G1 state reduplicate their DNA, 
leading to polyploidy and subsequent chromosomal instability. In the presence of wild-type 
p53, the polyploidy causes the activation of p21CIP1 and an irreversible arrest in cell cycle, 
or in cell death, thus preventing the propagation of aneuploidy56. 
 
Angiogenesis. The p53 protein has been shown to limit angiogenesis by few mechanisms: 
interfering with central regulators of hypoxia that mediate angiogenesis, inhibiting the 
production of proangiogenic factors, and directly increasing the production of endogenous 
angiogenesis inhibitors. The combination of these effects allows p53 to efficiently shut down 
the angiogenic potential of cancer cells. Wild-type p53 plays a role in limiting tumor 
vascularization. Mutant p53 plays a central role in promoting angiogenesis in colon cancer 
progression, and tumors carrying p53 mutations are more highly vascularised than tumors 
harboring wild-type p5359. The loss of TP53 appears to amplify the Hypoxia Inducible Factor 
(HIF) pathway. HIF-1α has been shown to be physically associated with p53 in immuno-
precipitation experiments. p53 promotes MDM2-mediated ubiquitination and degradation of 
HIF-1α, while loss of p53 leads to amplification of the HIF response60. 
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Figure 12: Activation and functions of p53. p53 has a key role in integrating the cellular responses (pink boxes) 
to different types of stress (blue boxes). Activation of p53 can result in a number of cellular responses, and 
different responses are induced by different stress signals. p53 can play a part in determining which response is 
induced through differential activation of target-gene expression. The role of p53 in tumor suppression, 
development and ageing is likely to depend on which cellular response is activated and on the context in which 
the activation occurs52. 
 
1.6.5 p53 inactivation in tumors 
Disruption of the p53 response pathway strongly correlates with tumorigenesis. Because of its 
prominent role as a tumor suppressor, p53 is functionally impaired by mutation or deletion in 
nearly 50% of human cancers. Restoring p53 function to cancer cells with mutant p53 has 
been shown to induce tumor cell death. Mutational inactivation is the most common 
mechanism and occurs in a large spectrum of sporadic and familial cancers of the breast, 
gastrointestinal tract, lung, brain, and soft tissues55. 
The evolutionarily conserved regions are the most frequent sites of mutations occurring in 
many human tumors. More than 90% of the substitution mutations reported so far in 
malignant tumors are clustered between exon 5 and 8 and are localized in four evolutionarily 
conserved regions. Among these conserved regions, at least four mutation “hot spots”, located 
at the amino-acid residues 175, 248, 273 and 282, have been identified in a variety of human 
neoplasms. Mutations in these “hot spot” codons account for approximately 30% of all p53 
mutations. In most tumors, both p53 alleles are inactivated, one through a point mutation, the 
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other through a deletion. In addition, most of these p53 mutations in human cancers are 
missense mutations, giving rise to an altered protein50.  
p53 mutations are much less frequent in leukemia than in other solid tumors. Although p53 
mutations occur in only 10%–15% of AML at diagnosis, they are associated with the most 
aggressive disease courses and drug resistance. Patients with p53 mutations are generally 
resistant to chemotherapy and have relatively short survival61,62. 
Alterations of the TP53 gene are of particular importance in the relapse stage of childhood 
ALL. TP53 alterations might be related to an increased proliferative capacity of leukemic 
blasts reflected by the observed shifted distribution of cell cycle phases to an increased 
percentage of cells in S and G2-M phase compared with that in patients with wild-type TP53. 
This might be caused by loss of p53 wild-type function abrogating cell cycle arrest in G0/G1 
phase and permitting passage through S phase. Therefore, TP53 alteration is a promising 
novel molecular marker for high risk of treatment resistance and failure with particular 
importance in the relapse stage of childhood ALL63. 
 
1.7 MDM2 
MDM2 was discovered on double minute chromosomes in a derivative cell line of NIH-3T3 
cells64. MDM2 belongs to the family of E3 ubiquitin ligases that contain a RING (really 
interesting new gene) domain and serves as the major E3 ubiqitin ligase for p53 
degradation65. 
 
1.7.1. MDM2 gene 
Human MDM2 gene consists of 12 exons that can generate many different proteins. 
Transcription of the MDM2 gene is controlled by two distinct promoters, referred to as P1 and 
P2 (Fig.13A). The P1 promoter controls basal expression of MDM2, and is situated upstream 
of the first exon of the MDM2 gene. The P2 promoter is highly regulated, is responsible for 
inducible expression of MDM2, and is found in the first intron. As the start site for translation 
is contained in exon 2, the transcripts expressed from both the P1 and P2 promoters encode 
identical full-length MDM2 proteins (Fig.13B). The p53 response elements are located 
upstream of the P2 promoter, and hence the p53-inducible expression of MDM2 can be 
monitored by expression levels of this specific transcript. A number of other signaling 
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pathways lead to the interaction of specific transcription factors, including RXR, AP-1, the 
Ets family, Smad2 and Smad3, with sequences contained within the first intron of the MDM2 
gene, activating transcription via the P2 promoter in addition to p53. A cluster of GC boxes 
lie further upstream, and have been implicated in the differential expression of MDM2 due to 
an interesting single nucleotide polymorphism, SNP309. When this polymorphism is a 
guanine, it results in the ability of Sp1 to regulate MDM2 expression. In contrast, a thymine 
in this position abrogates this, with a concomitant reduction in MDM2 levels66. 
 
 
Figure 13: MDM2 is transcriptionally regulated by multiple pathways. (A) P1 and P2 promoters regulate 
MDM2 expression. P1 controls basal expression of Mdm2 and is upstream of exon 1a. P2 is further downstream 
and uses a start site at an alternate first exon, 1b. P2 is inducible, and is regulated by response elements for a 
variety of transcription factors. A cluster of nGGGGC boxes act downstream from the Erk pathway. Three GC 
boxes control expression of MDM2, with one of these containing the site of a SNP309 that influences the 
binding of the Sp-1. (B) The two transcripts from the P1 and P2 promoters have distinct 5’UTR and different 
lengths66. 
 
1.7.2 MDM2 protein 
Human MDM2 is a 491 amino acid-long phosphoprotein (Fig.14) that interacts through its N-
terminal domain with an α-helix present in the N-terminal transactivation domain of p53. 
MDM2 is a ubiquitously expressed protein and plays an important role in tissue development. 
The most evolutionarily conserved domain of MDM2 is the C-terminal RING-finger domain, 
which possesses ubiquitin ligase activity towards p53. The MDM2 protein contains NLS and 
NES signals within its structure, and as a result MDM2 constantly shuttles the nucleus and the 
cytoplasm. Importantly, MDM2 itself is the product of a p53-inducible gene.  
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Thus, the two molecules are linked to each other through an autoregulatory negative feedback 
loop aimed at maintaining low cellular p53 levels in the absence of stress67. 
 
 
Figure 14: Domain structure of human MDM2. The N-terminal of MDM2 protein bind p53. MDM2 has a NLS. 
The central acidic region of MDM2 binds ribosomal proteins. The RING finger domain is required for Ubiquitin 
ligase MDM2 function68. 
 
1.7.3 MDM2 in tumors 
Human MDM2 is amplified and overexpressed in several human tumors. MDM2 
amplification has been identified in 19 tumor types with varying frequency, as well as in 
approximately one-third of human sarcomas, including those of soft tissue and bone.  
In addition, MDM2 expression can be upregulated independently of gene amplification and 
oncogenic splice variants have been identified. Alternative splicing of MDM2 and the 
generation of short proteins also occurs in many human tumors69. Overexpression of MDM2 
provides cells with a growth advantage, promotes tumorigenesis, and correlates with worse 
clinical prognosis and poor response to cancer therapy70. 
It has been shown that SNP309 correlates with the incidence of tumorigenesis in certain 
patient populations, thereby emphasizing the role of MDM2 as an oncogenic modifier in 
human cancer71. 
 
1.8 p53-MDM2 axis 
The MDM2-p53 interaction maps to the 106 amino acid-long N-terminal domain of MDM2 
and the N-terminus of the transactivation domain of p53 (residues 15–29). The direct 
interaction between p53 and MDM2 involves four key hydrophobic residues (Phe19, Leu22, 
Trp23 and Leu26) in a short amphipathic helix at the N-terminus of p53 and a small but deep 
hydrophobic pocket at the N-terminus of MDM2 (residues 25–109)72. 
Upon activation, p53 binds to the P2 promoter of the MDM2 gene and transcriptionally 
induces MDM2 protein expression. In turn, MDM2 protein binds to p53 protein and inhibits it 
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through multiple mechanisms. One of the consequences of MDM2 binding is to inhibit p53-
mediated transcriptional activity by blocking the p53-transcriptional coactivator interactions. 
This effect may be further enhanced by MDM2-mediated inhibition of the acetylation of p53 
by factors such as p300 and an ability of MDM2 to function directly as a transcriptional 
repressor. Another function of MDM2 that efficiently abolishes all p53 activity is the ability 
of MDM2 to target p53 for degradation through the ubiquitin-dependent proteasome pathway 
and this is likely to play a key role in maintaining p53 at low levels in normal cells. Inhibition 
of MDM2 in response to stress leads to the rapid stabilization of the p53 protein and 
activation of the p53 response49. 
In the absence of stress signals, p53 is bound to its negative regulator MDM2 that 
ubiquitinates p53, targeting it for degradation by the proteasome (Fig.15A). MDM2 harbors a 
self- and p53-specific E3 ubiquitin ligase activity within its evolutionarily conserved C-
terminal RING finger domain (Zinc-binding), and its RING finger is critical for its E3 ligase 
activity. MDM2 transfers monoubiquitin tags onto lysine residues mainly in the C-terminus of 
p53. Monoubiquitination is involved in receptor endocytosis, virus budding, transcription, 
DNA repair, and caspase recruitment in apoptosis, while polyubiquitination generally causes 
protein degradation. Because a chain of at least four ubiquitin molecules is believed to be 
necessary for efficient proteosomal degradation, other proteins must aid in polyubiquitination 
of p53; the p300/CREB binding protein (CBP) transcriptional coactivator proteins serving as 
scaffolding cooperates with MDM2 in polyubiquitination and degradation of p5372. 
Because MDM2 inhibits p53 activity, this forms a negative feedback loop that tightly 
regulates p53 function. In turn, decreased p53 activity results in decreased MDM2 to 
constitutive levels. MDM2 can also ubiquitinate itself and induce its own degradation.  
Upon DNA damage, p53 is post-translationally modified to inhibit interactions with MDM2. 
Several kinases also phosphorylate MDM2 and modulate interactions with p53. This ability of 
p53 to regulate MDM2 provides a feedback loop with an important role in regulating cell 
cycle progression and apoptosis73 (Fig.15B). 
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Figure 15: Schematic representation of the interactions between p53 and MDM2. (A) In the absence of stress 
signals, p53 is bound to its negative regulator MDM2. MDM2 ubiquitinates p53, targeting it for degradation by 
the 26 S proteasome. (B) Cellular stress signals, such as DNA-damage, lead to activation of ATM/ATR that 
mediates the phosphorylation of MDM2 and p53. Phosphorylated MDM2 undergoes auto-ubiquitination and 
degradation by the 26 S proteasome. Phosphorylated p53 undergoes nuclear localization, tetramerization, and 
binds to p53-responsive promoters to induce transcription of genes involved in the DNA-damage response74. 
 
 
1.9 Disruption of p53-MDM2 axis 
 
Pharmacological inhibitors of MDM2 have been developed that may enhance the anti-cancer 
activities of p53 (Fig.16). The potential effectiveness of MDM2 inhibitors is supported by the 
preclinical findings that genetic restoration of p53 activity results in rapid and extensive 
tumor regression in experimental mouse cancer models75,76. 
One potential advantage of the MDM2 inhibitors is that unlike many current forms of 
chemotherapy, they activate p53 without first damaging DNA. 
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Figure 16: Chemical structure of small-molecule MDM2 inhibitors.  
 
 
The first potent and selective small-molecule MDM2 antagonists, the Nutlins, were identified 
from a class of cis-imidazoline compounds. Nutlin-1 and Nutlin-2 are racemic mixtures and 
Nutlin-3a is an active enantiomer isolated from racemic Nutlin-3. These inhibitors could 
displace p53 from MDM2 in vitro with nanomolar potency (IC50=90 nM for Nutlin-3a, the 
active enantiomer of Nutlin-3). Crystal-structure studies demonstrated that Nutlins bind to the 
p53 pocket of MDM2 in a way that remarkably mimics the molecular interactions of the 
crucial amino acid residues from p53 (Fig.17). Nutlins have been shown to enter multiple 
types of cultured cells and inhibit the p53–MDM2 interaction in the cellular context with a 
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high degree of specificity, leading to stabilization of p53 and activation of the p53 pathway. 
Proliferating cancer cells were effectively blocked in G1 and G2 phases, and underwent 
apoptosis when exposed to low micromolar concentrations of Nutlins77. 
The Nutlins activate the p53 pathway and suppress tumor growth in vitro and in vivo. They 
represent valuable new tools for studying the p53 pathway and its defects in cancer.  
Nutlins induce p53-dependent apoptosis in human cancer cells but appear cytostatic to 
proliferating normal cells. MDM2 antagonists may have clinical utility in the treatment of 
tumors with wild-type p5378. 
Several studies have reported the use of MDM2 inhibitors to reactivate p53 pathway in 
cancer79,80,81,82. Thus it’s interesting to evaluate the Nutlin-3 effects on ALL tumor. 
 
 
 
Figure 17: Structural aspects of the p53–MDM2 interaction and Nutlin binding. (a) MDM2 and p53 interact 
with each other with their N-terminal domains through a well defined p53 binding pocket. The crystal structure 
of the binding revealed that three AA residues of the p53 peptide (green) are essential for the binding with 
MDM2, and they are inserted into a fairly deep cavity on the MDM2 surface (yellow). The figure depicts the 
most important functional domains of p53 and MDM2 proteins. (b) Nutlin (red) binds to the p53 pocket of 
MDM2 by mimicking the interaction of the three crucial AA residues from the p53 peptide (green)79.  
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2. AIMS 
 
The BCR-ABL TKIs are highly effective for treatment of Ph+ ALL, the most frequent and 
prognostically unfavorable subtype of ALL in adults. However, relapses with emerging TKI-
resistance mutations in the BCR-ABL kinase domain pose a significant problem.  
Here, we plan to investigate the efficacy and in vitro activity of a small-molecule antagonist 
of MDM2, Nutlin-3, that binds the p53-binding pocket of MDM2, thus inhibiting MDM2-
mediated degradation of p53. 
The rational of this study is based on the fact that theoretically hematological malignancies 
are attractive candidates for the MDM2 inhibitor-based therapy, because TP53 gene is 
relatively infrequently mutated. 
We performed a mutational screening of TP53 gene in B-ALL adult patients by Sanger 
Sequencing. 
Furthermore, previous studies using cell lines and primary samples from patients with various 
hematological malignancies (AML, ALL, chronic lymphocytic leukemia, multiple myeloma, 
and malignant lymphomas) have already shown that apoptosis is effectively induced by 
Nutlin-3. However, the effects of Nutlin-3 or other MDM2 inhibitors on BCR-ABL1-positive 
leukemic cells have not been reported so far. 
The main aim of this study has been to investigate the biological activity of Nutlin-3 in Ph+ 
and Ph- ALL. To this purpose, we assessed: 
-  mutational screening of TP53 gene in ALL cell lines and patients; 
- the in vitro activity of Nutlin-3 on Ph+ and Ph- cells; 
- the in vitro activity of Nutlin-3 on primary patient cells, resistant to previous TKIs 
treatment, with wild-type or mutated BCR-ABL; 
- the in vitro activity of the combination of Nutlin-3 and TKIs (Imatinib and Nilotinib) 
on Ph+ cells. 
- the determinants of Nutlin-3 efficacy and the signal transduction pathways which are 
affected by exposure to Nutlin-3. 
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2. MATERIALS AND METHODS 
 
PATIENTS 
Primary blast cells from 6 ALL patients were obtained, upon written informed consent, from 
bone marrow and peripheral blood samples by density gradient centrifugation over 
Lymphoprep (Nycomed UK, Birmingham).  
 
CELL LINES 
Human Ph+ (BV-173 and SUP-B15) and Ph- (NALM-6, NALM-9 and REH) ALL cell lines, 
and Ph+ CML cell line (K562) were used. 
BV-173 cells derived from the peripheral blood of a 45-year-old man with CML in blast crisis 
in 1980, contain the t(9;22) leading to BCR-ABL1 e13-a2 (b2-a2) fusion gene. SUP-B15 
derived from the bone marrow of a 9-year-old boy with ALL (B cell precursor ALL) in 
second relapse in 1984, described to carry the ALL-variant (m-bcr) of the BCR-ABL1 fusion 
gene (e1-a2). K562 cells were isolated by bone marrow of a 53-year-old female with CML in 
terminal blast crises. NALM-6 cells were established from the peripheral blood of a 19-year-
old man with ALL in relapse in 1976. NALM-9 cells derived from the peripheral blood of a 
26-year-old man with acute undifferentiated leukemia at diagnosis in 1988. REH were 
established from the peripheral blood of a 15-year-old North African girl with ALL at first 
relapse in 1973; carries t(12;21) leading to ETV6-RUNX1 (TEL-AML1) fusion gene. 
Ph+ cell lines, BV-173, SUP-B15 and K562, were maintained in RPMI 1640 medium 
supplemented with 20% fetal bovine serum, 1% penicillin streptomycin and 2 mM glutamine. 
Ph- ALL cell lines, NALM-6, NALM-9 and REH, were maintained in RPMI 1640 medium 
supplemented with 10% fetal bovine serum, 1% penicillin streptomycin and 2 mM glutamine. 
Cells were maintained at 37°C in 5% CO2. 
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METHODS: 
- RNA extraction 
Total RNA was extracted using the RNA Blood Mini Kit (Qiagen) from mononuclear cells 
isolated from peripheral blood or bone marrow aspirate samples. RNA was quantified using 
the Nanodrop Spectrophotometer and quality was assessed using the Nanodrop and by 
agarose gel electrophoresis. 
 
- Sequencing 
For the TP53 mutation screening, one μg of total RNA was used to synthesize the cDNA 
using High-Capacity cDNA Archive Kit (Applied Biosystems). p53 cDNA was amplified by 
PCR, in three overlapping shorter fragments covering the entire coding cDNA sequence 
(GenBank accession number NM_000546.4) and the untranslated exon 1, and one longer 
amplicon, using the primers shown in Table 1, using FastStart Taq DNA Polymerase Kit 
(Roche). PCR products were purified using QIAquick PCR purification kit (Qiagen) and then 
directly sequenced using an ABI PRISM 3730 automated DNA sequencer (Applied 
Biosystems).  
Primer 
ID 
 
 
Exon Sequence 5’- 3’ 
Tm 
(°C)  
Lenght 
(bp)  
Amplicon size  
(bp)  
p53 F1  
 
1 TGGATTGGCAGCCAGACT  60,36 18 
491 p53 R1  
 
5 GGGGGTGTGGAATCAACC  61,01 18 
p53 F2  
 
5 TCAACAAGATGTTTTGCCAACT  59,65 22 
482 p53 R2  
 
8 GCGGAGATTCTCTTCCTCTGT  59,97 21 
p53 F3  
 
8 GGTAATCTACTGGGACGGAACA  60,24 22 
498 p53 R3  
 
11 CTATTGCAAGCAAGGGTTCAA  60,25 21 
p53 F1 
 
1 TGGATTGGCAGCCAGACT 60,36 18 
1,317 p53 R3 
 
11 CTATTGCAAGCAAGGGTTCAA 60,35 21 
 
Table 1: sequence, melting temperature (Tm) and lenght (bp) of forward (F) and reverse (R) primers used for 
amplification of p53 transcripts and p53 amplicon size (bp). 
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- Quantitative Real Time PCR (qRT-PCR) 
One μg of total RNA was used to synthesize the first strand cDNA using Transcriptor First 
strand cDNA Synthesis Kit (Roche). BMI-1 expression was evaluated by qRT-PCR, 
performed on a Light Cycler 480 Roche with Taqman assay using 50 ng of cDNA for each 
sample. Thermal cycling conditions were as follows: denaturation of the cDNA at 95°C for 10 
min for activation of polymerase enzyme, followed by 40 cycles of amplification of the target 
cDNA at 95°C for 10 sec, 60°C for 10 sec, 72°C for 15 sec. Each sample was analyzed in 
triplicate. Relative mRNA expression values were normalized using GAPDH as reference 
gene and calculated on the basis of the E-ΔΔCp method. 
 
- MTS assay 
Cell viability was assessed by using colorimetric Methanethiosulfonate (MTS) test 
(Promega). This assay is composed of solutions of a tetrazolium compound [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, MTS] 
and an electron coupling reagent phenazine methosulfate (PMS). MTS is bioreduced by cells 
into a formazan product that is soluble in tissue culture medium. The absorbance of the 
formazan product at 490 nm was measured directly from 96-well assay plates. The conversion 
of MTS into the aqueous soluble formazan product is accomplished by dehydrogenase 
enzymes found in metabolically active cells. The quantity of formazan product as measured 
by the amount of 490 nm absorbance is directly proportional to the number of living cells in 
culture. Cells were cultured in 96-well plates at 50,000 cell/100 μl with different 
concentrations of drug, for different times and incubated at 37°C. Then, MTS (0.33 mg/ml) 
was added to each well and the cells were incubated for an additional 3 h. Following 
incubation, the optical density of the wells was read with microplate reader set a test 
wavelength of 490 nm. Cellular viability was calculated as a percentage of the viable cells 
compared to the untreated controls (DMSO 0.1%). 
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- Cell viability assay 
In ex-vivo primary leukemia cells the effects on cell viability was assessed by counting viable 
and non-viable cell numbers by the Trypan blue dye exclusion method. Cells were seeded in 
6-well plates at 500,000 cell/1 ml with increasing concentrations of drug for 24 hours and 
incubated at 37°C. Cellular viability was calculated as a percentage of the viable cells 
compared to the untreated controls (DMSO 0.1%). 
 
- Flow cytometry 
Flow cytometry was performed to analyze the apoptosis of cells after Nutlin-3a treatment. 
Apoptosis 
FITC Annexin V is a sensitive probe for identifying apoptotic cells, binding to negatively 
charged phospholipid surfaces with a higher affinity for phosphatidilserine than most other 
phosphoplipids. FITC Annexin V is used to quantitatively determine the percentage of cells 
within a population that are actively undergoing apoptosis. For analysis of apoptosis, ALL 
cells were seeded in 6-well-plate at 500,000 cell/1 ml and treated with increasing 
concentrations of Nutlin-3a or vehicle control (DMSO 0.1%), for different times. After 
treatment, cells were washed in 1X Binding Buffer and stained with FITC-Annexin 
V/propidium iodide (PI). Apoptosis was determined using PI exclusion assay. PI is a 
fluorescent vital dye that stains DNA, detected in the orange range of the spectrum using a 
562-588 nm band pass filter. Annexin V binds to cells early in apoptosis, and continues to be 
bound through cell death. PI is used in two-color Annexin V flow cytometric assays to 
distinguish cells that are in the earlier stages of apoptosis (Annexin V positive, PI negative) 
from those that are in the later stages of apoptosis or already dead (Annexin V positive, PI 
positive). Apoptosis was determined by flow cytometry. 
 
 
- Microarray  
Gene expression profiling was performed using Affymetrix GeneChip Human Gene 1.0 ST 
platform that ensures the coverage of 36,079 transcripts. Raw data were normalized by using 
the RMA algorithm and filtered. Genes differentially expressed were selected by analysis of 
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variance (ANOVA) (p-value threshold=0.05, Partek Genomics Suite). The most significantly 
involved process networks were defined by GeneGo software. 
 
- Western blotting 
Western blotting was performed using primary monoclonal antibodies directed toward 
MDM2 (Sigma Aldrich AB-166) at 1:1000 dilution; p53 (1C12) (Cell Signaling #2524) at 
1:500 dilution; BMI1 (D20B7) (Cell Signaling #6964) at 1:1000 dilution; caspase 3 (Cell 
Signaling #9662) at 1:1000 dilution; caspase 7 (Cell Signaling #9492) at 1:1000 dilution; 
p21/WAF1/Cip1 (Millipore 05-345) at 1:500 dilution; actin (Sigma Aldrich A 2066) at 1:1000 
dilution. ALL cell lines and ALL mononuclear cells were lysated in Lysis Buffer (50 mM 
TrisHCl pH 7.5, 150 nM NaCl, 1% Triton, 1mM EDTA, 0.1% SDS with protease and 
phosphatase inhibitor cocktail). The protein concentration of each sample was determined by 
Bradford assay (BioRad) and an equal amount of protein was transferred to Nitrocellulose 
membranes. The membranes were blocked with 5% milk in PBS at room temperature for 1 
hour, followed by incubation with primary antibodies at 4°C over-night and secondary 
antibodies at room temperature for 1 hour. The membranes were washed three times for 15 
minutes at room temperature with TPBS (PBS with 0,5% Tween-20) between the incubations, 
developed using the chemiluminescent detection reagent and scanned with 
chemiluminescence system. 
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3. RESULTS 
 
 
 
MDM2 overexpression in leukemia 
 
The web-based public database Oncomine (https://www.oncomine.org/) was queried for 
Mdm2 expression in the available leukemia datasets based on the comparison leukemia versus 
normal using a criterion of a 2 fold change and a p-value of 1E-4. Using these stringent 
criteria, we found that Mdm2 transcript is highly overexpressed in B-ALL if compared to 
normal peripheral blood samples (Fig.18), providing the rationale for its inhibition using 
MDM2 inhibitors. 
 
 
 
Figure 18: Oncomine expression analysis of Mdm2 levels between peripheral blood normal monunuclear cells 
and different subtypes of leukemia (including AML, B-ALL, T-ALL). Expression values are log transformed 
and median centered per array. Differential expression is identified by a permutation test and P values are 
calculated by t test and corrected for multiple comparisons by the method of false discovery rates. The group 
with the highest p-value is highlighted in blue. Mdm2 transcript levels are extracted from the study of Haferlach 
et al83. Dot points indicate the minimum and the maximum values in each dataset. 
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CDKN2A copy number state in leukemia cell lines 
 
The CDKN2A copy number state of BCR-ABL1 positive and negative cell lines was verified 
on http://cancer.sanger.ac.uk/cancergenome/projects/cell_lines/ website.  
Data available from the main Catalogue of somatic mutation in cancer (Cosmic) website 
report that all these leukemic cell lines harbor homozygous deletion of CDKN2A (Tab.2).  
 
 
CELL LINE GENE POSITION CNV TYPE 
BV-173 CDKN2A  9:21976871..22005395  0 Loss 
SUP-B15 CDKN2A  9:21976871..22005395  0 Loss 
NALM-6 CDKN2A  9:20300989..22140864  0 Loss 
NALM-9 CDKN2A  9:20300989..22140864  0 Loss 
REH CDKN2A  9:20677556..23118474  0 Loss 
K562 CDKN2A  9:20756547..26590984  0 Loss 
 
Table 2: CDKN2A Copy Number Variant (CNV) in BCR-ABL1-positive and negative cell lines reported on 
http://cancer.sanger.ac.uk/cancergenome/projects/cell_lines/ web site. This table indicates the homozygous 
deletion of CDKN2A gene at 9:20756547..26590984 position. 
 
 
P53 mutation screening in ALL cells  
 
BCR-ABL1-positive (BV-173, SUP-B15 and K562) and negative (NALM-6, NALM-19 and 
REH) cell lines were investigated for TP53 mutations by Sanger Sequencing. 
BV-173, SUP-B15, NALM-6 and NALM-19 cells showed wild-type p53. On the contrary, a 
p53 mutation with a heterozygous substitution of C > T was identified in REH cells at 
position:17:7578389 (Fig.19). This mutation resulted in a substitution of arginine in cysteine 
(R181C), causing functional inactivation of p53 protein. Finally, K562 cells were p53-null.  
Our results of p53 mutational screening are confirmed by p53 sequences reported in 
International Agency for Research on Cancer (IARC) database.  
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The IARC TP53 Mutation Database compiles all TP53 mutations that have been reported in 
the published literature since 1989. The following datasets are available: TP53 somatic 
mutations in sporadic cancers; TP53 germline mutation in familial cancers; common TP53 
polymorphisms identified in human populations; functional and structural properties of p53 
mutant proteins; TP53 gene status in human cell-lines; mouse-models with engineered TP53; 
experimentally-induced mutations. 
Moreover, wild type p53 sequences were observed in ALL patients. 
 
 
 
 
 
Figure 19: Electropherogram of p53 mutation in REH cells identified by Sanger Sequencing. The arrow 
indicates heterozygous substitution of C > T, at position:17:7578389. 
 
 
Inhibition of the p53-MDM2 interaction by MDM2 inhibitor induces growth arrest in 
Ph+ and Ph- leukemia cell lines with wild-type p53 
 
In order to investigate the effects of Nutlin-3a treatment, firstly we examined cell viability of 
leukemic cells. Ph+ and Ph- cell lines were incubated with increasing concentrations (0.1-10 
μM) of the active enantiomer (Fig.20A) of Nutlin-3 and with its inactive enantiomer 
(Fig.20B) for 24, 48 and 72 hours (hrs). The figure 20 represents an example of this 
experiment conducted in BV-173 cell line. Only the active enantiomer reduced BV-173 
viability in dose and time-dependent manner. The figure 20 and 21 represents the example of 
Nutlin-3 treatment in Ph+ and Ph- ALL cells, BV-173 and NALM-6, respectively. 
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Figure 20: Cell viability in Ph+ ALL cell line, BV-173, after incubation with active (A) or inactive (B) 
enantiomer of Nutlin-3 at increasing concentration (0.1 μM-10 μM) for 24 hrs, 48 hrs and 72 hrs. 
 
 
 
Figure 21: Cell viability of Ph- ALL cell line, NALM-6, after Nutlin-3a treatment at increasing concentration 
(0.5 μM-5 μM) for 24 hrs and 48 hrs. 
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MDM2 inhibition resulted in a dose and time-dependent antiproliferative and cytotoxic 
activity with IC50 at 24 hrs ranging from 1.349 μM for BV-173 and 1.621 μM for SUP-B15 
(Fig.22A), to 2.7 for NALM-6 and 3.7 μM for NALM-19 (Fig.22B). By contrast, no 
significant changes in cell viability were observed in K562 p53-null (Fig.22A) and REH p53-
mutated cells (Fig.22B) after incubation with MDM2 inhibitor. 
These results showed that Nutlin-3 efficiently inhibited growth of Ph+ and Ph- ALL cells, with 
wild type p53. REH and K562 cells, which have mutant p53, did not respond to the MDM2 
inhibitor, confirming that the p53 pathway can be activated by Nutlin-3 only in cells with 
wild-type p53. 
 
      
 
  
 
Figure 22: Cell viability of  Ph+ (A) and Ph- (B) leukemia cell lines, with wild-type or mutated p53, after Nutlin-
3a treatment.  At 24 hrs, IC50 was 1.349 μM for BV-173 and 1.621 μM for SUP-B15 (A), 2.789 μM for NALM-6 
and 3.781 μM for NALM-19 (B). K562 p53-null (A) and REH (B), p53-mutated cell lines did not respond to the 
Nutlin-3a. 
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Inhibition of the p53-MDM2 interaction by MDM2 inhibitor induces apoptosis in Ph+ 
and Ph- leukemia cell lines with wild-type p53 and in Ph+ ALL patients 
 
To understand the cell viability reduction as a consequence of Nutlin-3a treatment in ALL 
cells, we analyzed the apoptosis induction after MDM2 inhibitor treatment in Ph+ and Ph- 
ALL cell line and in primary Ph+ cells. These experiments demonstrated that Nutlin-3a 
induced a time and dose-dependent apoptosis in ALL cells with wild type p53. The figures  
23 and 24 show two examples of apoptosis induction in Ph+ and Ph- ALL cells, BV-173 and 
NALM-6, respectively. By contrast, ALL cells with mutation in p53, such as REH cells 
shown in figure 25, did not respond to Nutlin-3a and consequently, p53 pathway is not 
activated. 
 
 
 
Figure 23: Induction of apoptosis in BV-173, Ph+ cell line, after 24 hrs and 48 hrs of Nutlin-3a incubation at 
1μM, 2 μM and 5 μM concentration, or DMSO control 0.1%. The percentage of cells undergoing apoptosis was 
detected using Annexin V (Ann V) and propidium iodide (PI) staining and normalized to DMSO control. 
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Figure 24: Induction of apoptosis in NALM-6, Ph- cell line, after 24 hrs and 48 hrs of Nutlin-3a incubation at 
1μM, 2 μM and 5 μM concentration, or DMSO control 0.1%. The percentage of cells undergoing apoptosis was 
detected using Ann V and PI staining and  normalized to DMSO control. 
 
 
 
 
 
 
Figure 25: Induction of apoptosis in REH, Ph- cell line, after 24 hrs and 48 hrs of Nutlin-3a incubation at 1μM, 2 
μM and 5 μM concentration, or DMSO control 0.1%. The percentage of cells undergoing apoptosis was detected 
using Ann V and PI staining and  normalized to DMSO control. 
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Inhibition of the p53-MDM2 interaction by MDM2i induces growth arrest of primary 
Ph+ ALL cells 
 
Next, we analyzed the effect of Nutlin-3a on cell viability in ALL cells. Primary cells isolated 
by Ph+ ALL (patients 2, 4, 5, 6) and Ph- ALL (patients 1 and 3) patients were incubated with 
increasing concentration of Nutlin-3a (1µM, 2µM e 5µM) and with DMSO vehicle (0.1%). 
(Fig.26) for 24 hrs. 
 
 
 
Figure 26: Cell viability in primary cells isolated by Ph+ and Ph- ALL patients compared to DMSO 0.1% 
control, in response to increasing concentration (1μM, 2 μM and 5 μM) of 24 hrs of Nutlin-3a treatment. The 
control sample is represented by a patient in disease remission. 
 
These results demonstrated that, generally, Nutlin-3a induces a reduction of cell viability in 
ALL patients compared to DMSO 0.1% control. Cell viability reduction is dose-dependent in 
almost all treated patients, except for patient 3 in which an increase of viability in 
concomitance with the incubation of increasing dose of the MDM2 inhibitor has been 
observed. All these patients showed p53 wild-type sequence.  
Therefore, the different drug sensitivity may be attributed to other molecular causes that will 
be further investigated. The control sample is represented by peripheral blood mononuclear 
cells from a patient in disease remission. In this sample no viability reduction after MDM2 
inhibitor treatment was observed, confirming the lack of induction of apoptosis Nutlin-3a-
mediated in normal cells.  
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For some of these samples it has been possible to evaluate the efficacy of Nutlin-3a in 
modulation of protein expression. After treatment, the MDM2 expression was reduced; by 
contrast, p53 levels rised in p53 wild-type cells. Consequently, p53 induced the activation of 
its downstream pathway, like demonstrated by an increased expression of proapoptotic 
proteins and key regulators of cell cycle arrest, like p21 (Fig.27A), but not in resistant cells 
with mutation in p53 (Fig.27B).  
 
 
 
 
Figure 27: MDM2, p53 and p21 expression after 24 hrs of exposure to MDM2 inhibitor at 1 µM, 2 µM, and 5 
µM concentration or to DMSO vehicle in sensitivity Ph+ (A), and in resistant Ph- ALL cells (B). Actin was used 
for normalization.  
 
Combination of Nutlin-3 and TKIs induces dose-dependent reduction in cell viability in 
BV-173 Ph+ ALL cell line 
 
The combination effect of Nutlin-3a and TKIs, Imatinib and Nilotinib, was evaluated on BV-
173 Ph+ ALL cell line viability (Fig.28). Treatment with increasing concentration of Nutlin-3a 
alone (1 μM and 2 μM) (Fig.28A), reduced the BV-173 viability of 15% and 33%, 
respectively, while single treatment with Imatinib (IM) (at 1 μM concentration) or Nilotinib 
(AMN) (at 100 nM concentration) reduced the BV-173 viability of 59% and 43%, 
respectively. The results showed that combination of increasing concentration of Nutlin-3a (1 
μM and 2 μM) and Imatinib (at 1 μM concentration) reduced the BV-173 viability of 65% and 
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66%, respectively; instead, Nutlin-3a (1 μM and 2 μM) and AMN (100 nM) reduced the BV-
173 viability of 63% and 71%, respectively (Fig.28B).  
 
 
Figure 28: Cell viability in BV-173, Ph+ ALL cell line, treated with Nutlin-3a (A) at 1 μM and 2 μM 
concentration, with Imatinib (IM) (1 μM), with Nilotinib (AMN) (100 nM), alone, or Nutlin-3a (1 μM and 2 μM) 
in combination with IM (1 μM), or with AMN (100 nM) (B).  
 
Nutlin-3a induces reduction in cell viability in primary blast cells from Ph+ ALL 
patients with the T315I BCR-ABL kinase domain mutation 
 
The dose-dependent reduction in cell viability was confirmed in primary blast cells from Ph+ 
ALL patients with the T315I Bcr-Abl kinase domain mutation found to be insensitive to the 
available TKIs (Fig.29). Nutlin-3a treatment, at 1 μM and 5 μM concentrations, was 
performed on primary blast cells of two Ph+ ALL patients. In particular, in one case Nutlin-3a 
reduced cell viability of 27% and 73% at 1 μM and 5 μM concentrations, respectively; in a 
second case Nutlin-3a reduced cell viability of 65% and 82% at 1 μM and 5 μM 
concentrations, respectively.  
Thus, the results demonstrated that Nutlin-3a reduced cell viability in dose-dependent 
manner. 
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Figure 29: Cell viability of  primary blast cells isolated by two Ph+ ALL patients with T315I Bcr-Abl mutation 
after 24 hrs of MDM2 inhibitor treatment at 1 μM and 5 μM concentration. In one case Nutlin-3a reduced cell 
viability of 27% and 73% at 1 μM and 5 μM concentrations, respectively; in second case Nutlin-3a reduced cell 
viability of 65% and 82% at 1 μM and 5 μM concentrations, respectively. 
 
Gene expression signature associated with response to MDM2 inhibitor 
 
In order to better elucidate the implications of p53 activation and to identify biomarkers of 
clinical activity, microarray analysis was performed, comparing sensitive cell lines (BV-173 
and SUPB-15) after 24 hrs of exposure to 2 µM Nutlin-3a and their untreated counterparts 
(DMSO 0.1%). A total of 621 genes (48% down-regulated versus 52% up-regulated) were 
differentially expressed (p< 0.05) (Fig.30). They include genes involved in cell cycle and 
apoptosis control (e.g. Histone H1, TOP2, GAS41, H2AFZ) and in the down-regulation of the 
Hedgehog signaling (e.g. BMI1, BMP7, CDKN1C, POU3F1, CTNNB1, PTCH2) with a strong 
repression of stemness genes and re-activation of INK4/ARF (Tab.3). Both GAS41 (growth-
arrest specific 1 gene) and BMI1 (a polycomb ring-finger oncogene) are repressors of 
INK4/ARF and p21 genes and their aberrant expression has found to contribute to stem cell 
state in tumor cells84,85. Additionally, experimental reduction of BMI1 protein levels have 
been demonstrated to result in apoptosis in tumor cells and increases susceptibility to 
cytotoxic agents and radiation therapy86. 
In our data, BMI-1 and GAS41 were strongly down-regulated (fold-change -1.35 and -1.11, 
respectively; p-value 0.02 and 0.03, respectively) after in vitro treatment as compared to 
control cells (Tab.3), suggesting that these genes have a potential as new biomarkers of 
activity.  
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Figure 30: Heat-map showing differentially expressed genes between control (DMSO) and sensitive cells 
treated with 2 µM of Nutlin-3a for 24 hrs. 
 
  
 
Table 3: genes involved in transcription and chromatin modification. Both GAS41and BMI1 were down-
regulated after in vitro treatment (fold-change -1.35 and -1.11, respectively; p-value 0.02 and 0.03, respectively). 
They are repressors of INK4/ARF and p21 genes.  
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Nutlin-3a induces a down-regulation of BMI-1 in ALL patients 
 
To validate microarray data analysis and given the importance of BMI-1 in the control of 
apoptosis, we investigated its pattern in primary blast cells of 5 ALL patients.   
ALL cells were treated with Nutlin-3a at 5 μM concentration for 24 hrs, and subsequently 
BMI-1 expression was evaluated (Fig.31).  
BMI-1 gene expression was down-regulated in 3 of 5 ALL patients after Nutlin-3a treatment, 
if compared with their untreated counterparts (DMSO 0.1%). This result confirmed a marked 
decrease of BMI-1 in leukemia cells. 
 
 
Figure 31: BMI-1 relative expression in primary cells isolated by 5 ALL patients after 24 hrs of Nutlin-3a 
treatment at 5 μM concentration. 
 
Nutlin-3a decreases BMI-1 protein levels in ALL with wild-type p53 
BMI-1 protein expression decreased in ALL cell lines and primary blast cells with wild-type 
p53. The figure 32A represents an example of this experiment conducted in sensitive BV-173 
cell line. Noteworthy, the BMI-1 levels remained constant in REH resistant cells (Fig.32B). 
BMI-1 expression is markedly reduced in sensitive cells and it may be used as a biomarker of 
response. 
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Figure 31: MDM2, p53, p21 and BMI-1 expression after 24 hrs of exposure to MDM2 inhibitor at 1 µM, 2 µM, 
and 5 µM concentration or to DMSO vehicle in sensitivity Ph+ (A), and in resistant Ph- ALL cells (B). Actin was 
used for normalization.  
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5. DISCUSSION 
 
 
The BCR-ABL fusion gene, generated by a reciprocal t(9;22) chromosomal translocation 
causing the Philadelphia chromosome, is the molecular signature of CML and is also 
observed in 30–40% of ALL. The BCR-ABL fusion protein is a tyrosine kinase that is 
constitutively activated and confers survival and proliferation advantages to hematopoietic 
cells, thus contributing to leukemogenesis3. Imatinib and second TKIs specifically inhibit the 
BCR-ABL tyrosine kinase showing unprecedented efficacy for the treatment of these 
leukemias11. However, BCR-ABL transcripts remain detectable by qRT-PCR in the majority 
of responding patients and resistance may develop in significant portions of patients with 
CML in advanced stages or with Ph+ ALL, mostly due to the emergence of mutations in the 
BCR-ABL kinase domain, including the most frequent E255K, T315I and F317L mutations, 
that may inhibit binding of TKIs to the kinase domain18. 
Novel treatment strategies able to overcome or synergize with current TKI-based therapies are 
required to improve cure rates. An attractive approach is represented by the small-molecule 
MDM2 antagonists, which target the p53-MDM2 interaction, leading to the activation of p53-
mediated apoptosis in tumors with overexpressed MDM2, but wild-type p5375,77. 
The human p53 tumor suppressor protein, the product of the TP53 gene, is one of the most 
important molecules in human cancers. It is known as the “guardian of the genome”, which 
plays a central role in the regulation of cell cycle, apoptosis, DNA repair, senescence and 
angiogenesis in response to diverse stresses54. Deleted or mutated TP53 has been shown in 
∼50% of human tumors. Although 50% of all human tumors express wild-type p53, many are 
thought to have inadequate p53 function due to abnormalities in p53 regulation or defective 
signaling in the p53 pathway55.  
One mechanism for suppressing p53 uses its negative regulator murine double minute 2 gene 
product, MDM2, which negatively modulates p53 by binding directly to and decreasing p53 
stability49. Overexpression of MDM2 in animal models increases tumor formation. Somatic 
mutations in the MDM2 gene have been identified in adenocarcinoma of the lung, and 
MDM2 overexpression or amplification has been frequently observed in multiple 
malignancies70. In addition, a germline single nucleotide polymorphism (SNP309 T>G; 
rs2279744) in the promoter region of MDM2 has been identified. The presence of the G allele 
increases MDM2 gene expression and is associated with an earlier age of onset of human 
54 
 
cancers71. MDM2 is inhibited by the tumor suppressor p14ARF , which can bind to and prevent 
MDM2-mediated ubiquitination of p53 and activate p53 responses31. 
ARF is an alternate reading frame protein expressed from the INK4a locus. Hyperproliferative 
signals lead to the increased expression of ARF, which inhibits MDM2 by blocking its E3 
ubiquitin ligase activity, uncoupling the p53–MDM2 interaction and sequestering MDM2 in 
the nucleolus, thereby segregating it from nucleoplasmic p5331,32. 
In normal cells, tight feedback regulation of the ARF/MDM2/p53 axis controls p53 activity 
through a host of protein modifications (eg, phosphorylation, acetylation, sumoylation) as 
well as ubiquitination and deubiquitination and limits the effects of p53 activation31,33. 
Recently, ARF deletions have been described to frequently occur in patients with Ph+ ALL 
and contribute to resistance to targeted therapy in ALL induced by BCR-ABL28. 
Because the interaction between MDM2 and p53 is a primary mechanism for inhibition of the 
p53 function in cancers retaining wild-type p53, targeting the MDM2-p53 interaction by 
small molecules to reactivate p53 has emerged as a promising new cancer therapeutic 
strategy. 
Small-molecule inhibitors have been identified that specifically target the E3 ligase activity of 
MDM2. The first potent and selective small-molecule MDM2 antagonists, the Nutlins, were 
identified from a class of cis-imidazoline compounds. These inhibitors could displace p53 
from MDM2 in vitro with nanomolar potency (IC50=90 nM for Nutlin-3a, the active 
enantiomer of Nutlin-3). Crystal-structure studies demonstrated that Nutlins bind to the p53 
pocket of MDM2 in a way that remarkably mimics the molecular interactions of the crucial 
amino acid residues from p53. Nutlins have been shown to enter multiple types of cultured 
cells and inhibit the p53–MDM2 interaction in the cellular context with a high degree of 
specificity, leading to stabilization of p53 and activation of the p53 pathway. Proliferating 
cancer cells were effectively blocked in G1 and G2 phases, and underwent apoptosis when 
exposed to low micromolar concentrations of Nutlins77. 
Based on these previous findings, in this study we aimed to investigate the efficacy of MDM2 
inhibitors for ALL cells. We demonstrated that Nutlin-3a induces growth arrest and apoptosis 
in Ph+ and Ph- leukemia cells, with wild-type p53, in dose and time dependent manner. By 
contrast, no significant changes in cell viability and apoptosis were observed in p53-null and 
p53-mutated cell lines after incubation with MDM2 inhibitor, confirming that the p53 
pathway can be activated by Nutlin-3 only in cells with wild-type p53.  
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We evaluated also the combination of Nutlin-3a and TKIs demonstrating that the combination 
between Nutlin-3a and Imatinib or Nilotinib, induced dose-dependent reduction in Ph+ ALL 
cell viability, indicating a synergistic effect between these drugs. 
Given the clinical importance of BCR-ABL1 mutations, we tested the efficacy of Nutlin-3a in 
primary blast cells isolated by ALL patients with T315I mutation that confers resistance to 
available TKIs. We observed that Nutlin-3a induced cell viability reduction, supposing a 
possible alternative treatment in resistant patients to TKIs treatment. 
In this study we demonstrated that treatment with Nutlin-3a in ALL cell lines and also in 
primary blast cells isolated by ALL patients induced the activation of apoptosis mechanism 
mediated by p53 pathway with consequent increase of proapoptotic proteins and key 
regulators of cell cycle arrest. 
Gene expression profiling analysis, conducted in Nutlin-3a sensitive cells, permitted to better 
elucidate the implications of p53 activation and to identify possible biomarkers of clinical 
activity. In particular, we studied BMI-1, involved in control of apoptosis and in regulation of 
CDKN2A and p21 genes85. BMI-1 expression is markedly reduced in sensitive cells and it 
may be used as a biomarker of response. Evaluation of its expression before and after 
treatment in clinical settings will better gain insight into its role. 
Our findings provide a strong rational for further clinical investigation of Nutlin-3a in Ph+ and 
Ph-ALL. 
In conclusion, small-molecule MDM2 antagonists, which target the p53-MDM2 interaction, 
leading to the activation of p53-mediated apoptosis, could be able to overcome or synergize 
with current TKIs-based therapies in Ph+ ALL patients with wild-type p53. Furthermore, 
Nutlin-3 may provide a novel therapeutic tool for the therapy of Ph- ALL patients with wild-
type p53. 
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